1 Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R. & Walters, E. E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617–627 (2005).

2 Kessler, R. C. Epidemiology of women and depression. J. Affect. Disord. 74, 5–13 (2003).

3 Murray, C. J. et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA 310, 591–608 (2013).

4 Russo, S. J. & Nestler, E. J. The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14, 609–625 (2013).

5 Krishnan, V. & Nestler, E. J. The molecular neurobiology of depression. Nature 455, 894–902 (2008).

6 Duman, R. S. & Aghajanian, G. K. Synaptic dysfunction in depression: potential therapeutic targets. Science 338, 68–72 (2012).

7 Duman, R. S. & Li, N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Phil. Trans. R. Soc. B 367, 2475–2484 (2012).

8 Schmidt, H. D., Shelton, R. C. & Duman, R. S. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36, 2375–2394 (2011).

9 Foley, D. L. et al. Major depression and associated impairment: same or different genetic and environmental risk factors? Am. J. Psychiatry 160, 2128–2133 (2003).

10 Sullivan, P. F., Neale, M. C. & Kendler, K. S. Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 157, 1552–1562 (2000).

11 Gilman, S. E. et al. Psychosocial stressors and the prognosis of major depression: a test of Axis IV. Psychol. Med. 43, 303–316 (2013).

12 McLaughlin, K. A., Conron, K. J., Koenen, K. C. & Gilman, S. E. Childhood adversity, adult stressful life events, and risk of past-year psychiatric disorder: a test of the stress sensitization hypothesis in a population-based sample of adults. Psychol. Med. 40, 1647–1658 (2010).

13 Kendler, K. S. & Halberstadt, L. J. The road not taken: life experiences in monozygotic twin pairs discordant for major depression. Mol. Psychiatry 18, 975–984 (2013).

14 Duman, R. S. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin. Neurosci. 11, 239–255 (2009).

15 Christoffel, D. J., Golden, S. A. & Russo, S. J. Structural and synaptic plasticity in stress-related disorders. Rev. Neurosci. 22, 535–549 (2011).

16 Hodes, G. E., Kana, V., Menard, C., Merad, M. & Russo, S. J. Neuroimmune mechanisms of depression. Nat. Neurosci. 18, 1386–1393 (2015).

17 Wohleb, E. S., McKim, D. B., Sheridan, J. F. & Godbout, J. P. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior. Front. Neurosci. 8, 447 (2015).

18 Maes, M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 11–38 (1995).

19 Howren, M. B., Lamkin, D. M. & Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71, 171–186 (2009).

20 Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446–457 (2010).

21 Capuron, L. & Dantzer, R. Cytokines and depression: the need for a new paradigm. Brain Behav. Immun. 17 (Suppl. 1), 119–124 (2003).

22 Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56 (2008).

23 Miller, A. H., Maletic, V. & Raison, C. L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732–741 (2009).

24 Iwata, M., Ota, K. T. & Duman, R. S. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav. Immun. 31, 105–114 (2013).

25 Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597–605 (2011).

26 Dunn, J. H., Ellis, L. Z. & Fujita, M. Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 314, 24–33 (2012).

27 da Silva, J., Goncalves-Pereira, M., Xavier, M. & Mukaetova-Ladinska, E. B. Affective disorders and risk of developing dementia: systematic review. Br. J. Psychiatry 202, 177–186 (2013).

28 Leonard, B. E. Inflammation, depression and dementia: are they connected? Neurochem. Res. 32, 1749–1756 (2007).

29 Ownby, R. L., Crocco, E., Acevedo, A., John, V. & Loewenstein, D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch. Gen. Psychiatry 63, 530–538 (2006).

30 Goodman, W. K. & Charney, D. S. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. J. Clin. Psychiatry 46, 6–24 (1985).

31 Heninger, G. R., Delgado, P. L. & Charney, D. S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29, 2–11 (1996).

32 Maas, J. W. Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. Arch. Gen. Psychiatry 32, 1357–1361 (1975).

33 Kendell, S. F., Krystal, J. H. & Sanacora, G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin. Ther. Targets 9, 153–168 (2005).

34 Northoff, G. & Sibille, E. Why are cortical GABA neurons relevant to internal focus in depression? A cross-level model linking cellular, biochemical and neural network findings. Mol. Psychiatry 19, 966–977 (2014).

35 Sanacora, G. & Saricicek, A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol. Disord. Drug Targets 6, 127–140 (2007).

36 Butler, P. W. & Besser, G. M. Pituitary–adrenal function in severe depressive illness. Lancet 1, 1234–1236 (1968).

37 Dinan, T. G. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br. J. Psychiatry 164, 365–371 (1994).

38 Price, J. L. & Drevets, W. C. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn. Sci. 16, 61–71 (2010).

39 Ressler, K. J. & Mayberg, H. S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat. Neurosci. 10, 1116–1124 (2007).

40 Shin, L. M. & Liberzon, I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 35, 169–191 (2010).

41 Magarinos, A. M., McEwen, B. S., Flugge, G. & Fuchs, E. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J. Neurosci. 16, 3534–3540 (1996).

42 Radley, J. J. et al. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neuroscience 125, 1–6 (2004).

43 Kang, H. J. et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat. Med. 18, 1413–1417 (2012).

44 Duric, V. et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int. J. Neuropsychopharmacol. 16, 69–82 (2012).

45 Gould, E., Tanapat, P., McEwen, B. S., Flugge, G. & Fuchs, E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc. Natl Acad. Sci. USA 95, 3168–3171 (1998).

46 Gould, E., McEwen, B. S., Tanapat, P., Galea, L. A. & Fuchs, E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J. Neurosci. 17, 2492–2498 (1997).

47 Magarinos, A. M. & McEwen, B. S. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 69, 89–98 (1995).

48 Wellman, C. L. Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J. Neurobiol. 49, 245–253 (2001).

49 Vyas, A., Mitra, R., Shankaranarayana Rao, B. S. & Chattarji, S. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J. Neurosci. 22, 6810–6818 (2002).

50 Roozendaal, B., McEwen, B. S. & Chattarji, S. Stress, memory and the amygdala. Nat. Rev. Neurosci. 10, 423–433 (2009).

51 Krishnan, V. et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131, 391–404 (2007).

52 Malberg, J. E., Eisch, A. J., Nestler, E. J. & Duman, R. S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20, 9104–9110 (2000).

53 Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805–809 (2003).

54 Navarria, A. et al. Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol. Dis. 82, 254–261 (2015).

55 Voleti, B. et al. Scopolamine rapidly increases Mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 74, 742–749 (2013).

56 Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959–964 (2010).

57 Dantzer, R., O'Connor, J. C., Lawson, M. A. & Kelley, K. W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36, 426–436 (2011).

58 DellaGioia, N. & Hannestad, J. A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci. Biobehav. Rev. 34, 130–143 (2010).

59 Steptoe, A., Hamer, M. & Chida, Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav. Immun. 21, 901–912 (2007).

60 Felger, J. C. et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatry http://dx.doi.org/10.1038/mp.2015.168 (2015). This paper provides initial clinical evidence linking elevated peripheral markers of inflammation with decreases in the functional connectivity of PFC–striatum pathways, which correlate with depressive symptom severity.

61 Lamers, F. et al. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol. Psychiatry 18, 692–699 (2013). A clinical study showing that subtypes of depression have characteristic immune and hormone biomarkers, potentially reflecting varied pathophysiological mechanisms.

62 Gold, P. W. The organization of the stress system and its dysregulation in depressive illness. Mol. Psychiatry 20, 32–47 (2015).

63 Torres-Platas, S. G., Cruceanu, C., Chen, G. G., Turecki, G. & Mechawar, N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav. Immun. 42, 50–59 (2014).

64 Steiner, J. et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 42, 151–157 (2008).

65 Setiawan, E. et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72, 268–275 2015).

66 Martinez, J. M., Garakani, A., Yehuda, R. & Gorman, J. M. Proinflammatory and “resiliency” proteins in the CSF of patients with major depression. Depress. Anxiety 29, 32–38 (2012).

67 Carpenter, L. L., Heninger, G. R., Malison, R. T., Tyrka, A. R. & Price, L. H. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J. Affect. Disord. 79, 285–289 (2004).

68 Hampel, H., Kotter, H. U. & Moller, H. J. Blood–cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. Alzheimer Dis. Assoc. Disord. 11, 78–87 (1997).

69 Haroon, E. et al. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol. Psychiatry http://dx.doi.org/10.1038/mp.2015.206 (2016).

70 Shelton, R. C. et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 16, 751–762 (2011).

71 Kim, S., Hwang, Y., Webster, M. J. & Lee, D. Differential activation of immune/inflammatory response-related co-expression modules in the hippocampus across the major psychiatric disorders. Mol. Psychiatry 21, 376–385 (2016).

72 Beumer, W. et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J. Leukoc. Biol. 92, 959–975 (2012).

73 Sternberg, E. M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6, 318–328 (2006).

74 Irwin, M. R. & Cole, S. W. Reciprocal regulation of the neural and innate immune systems. Nat. Rev. Immunol. 11, 625–632 (2011).

75 Erickson, M. A., Dohi, K. & Banks, W. A. Neuroinflammation: a common pathway in CNS diseases as mediated at the blood–brain barrier. Neuroimmunomodulation 19, 121–130 (2012).

76 Quan, N. Immune-to-brain signaling: how important are the blood–brain barrier-independent pathways? Mol. Neurobiol. 37, 142–152 (2008).

77 Schwartz, M., Kipnis, J., Rivest, S. & Prat, A. How do immune cells support and shape the brain in health, disease, and aging? J. Neurosci. 33, 17587–17596 (2013).

78 Prinz, M., Priller, J., Sisodia, S. S. & Ransohoff, R. M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 14, 1227–1235 (2011).

79 Schiltz, J. C. & Sawchenko, P. E. Signaling the brain in systemic inflammation: the role of perivascular cells. Front. Biosci. 8, s1321–s1329 (2003).

80 Serrats, J. et al. Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron 65, 94–106 (2010).

81 Schwartz, M., London, A. & Shechter, R. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience 158, 1133–1142 (2009).

82 Kipnis, J., Gadani, S. & Derecki, N. C. Pro-cognitive properties of T cells. Nat. Rev. Immunol. 12, 663–669 (2012).

83 Dhabhar, F. S., Malarkey, W. B., Neri, E. & McEwen, B. S. Stress-induced redistribution of immune cells — from barracks to boulevards to battlefields: a tale of three hormones — Curt Richter Award winner. Psychoneuroendocrinology 37, 1345–1368 (2012).

84 Dhabhar, F. S. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation 16, 300–317 (2009).

85 Trottier, M. D., Newsted, M. M., King, L. E. & Fraker, P. J. Natural glucocorticoids induce expansion of all developmental stages of murine bone marrow granulocytes without inhibiting function. Proc. Natl Acad. Sci. USA 105, 2028–2033 (2008).

86 Engler, H. et al. Interleukin-1 receptor type 1-deficient mice fail to develop social stress-associated glucocorticoid resistance in the spleen. Psychoneuroendocrinology 33, 108–117 (2008).

87 Engler, H., Engler, A., Bailey, M. T. & Sheridan, J. F. Tissue-specific alterations in the glucocorticoid sensitivity of immune cells following repeated social defeat in mice. J. Neuroimmunol. 163, 110–119 (2005).

88 Stark, J. L., Avitsur, R., Hunzeker, J., Padgett, D. A. & Sheridan, J. F. Interleukin-6 and the development of social disruption-induced glucocorticoid resistance. J. Neuroimmunol. 124, 9–15 (2002).

89 Stark, J. L. et al. Social stress induces glucocorticoid resistance in macrophages. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R1799–R1805 (2001).

90 Felten, D. L., Felten, S. Y., Carlson, S. L., Olschowka, J. A. & Livnat, S. Noradrenergic and peptidergic innervation of lymphoid tissue. J. Immunol. 135, 755s–765s (1985).

91 Nance, D. M. & Sanders, V. M. Autonomic innervation and regulation of the immune system (1987–2007). Brain Behav. Immun. 21, 736–745 (2007).

92 Hanke, M. L., Powell, N. D., Stiner, L. M., Bailey, M. T. & Sheridan, J. F. Beta adrenergic blockade decreases the immunomodulatory effects of social disruption stress. Brain Behav. Immun. 26, 1150–1159 (2012).

93 Grisanti, L. A. et al. Pro-inflammatory responses in human monocytes are β1-adrenergic receptor subtype dependent. Mol. Immunol. 47, 1244–1254 (2010).

94 Spiegel, A. et al. Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling. Nat. Immunol. 8, 1123–1131 (2007).

95 Katayama, Y. et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124, 407–421 (2006).

96 Powell, N. D. et al. Social stress up-regulates inflammatory gene expression in the leukocyte transcriptome via β-adrenergic induction of myelopoiesis. Proc. Natl Acad. Sci. USA 110, 16574–16579 (2013).

97 Heidt, T. et al. Chronic variable stress activates hematopoietic stem cells. Nat. Med. 20, 754–758 (2014). A preclinical study showing that psychological stress can induce the proliferation and mobilization of haematopoietic immune cells through SNS signalling, resulting in increased numbers of circulating monocytes and granulocytes.

98 Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612–616 (2009).

99 Johnson, J. D. et al. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience 135, 1295–1307 (2005).

100 Miller, G. E. et al. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-κB signaling. Biol. Psychiatry 64, 266–272 (2008).

101 Pace, T. W. et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 163, 1630–1633 (2006).

102 Wohleb, E. S. et al. Knockdown of interleukin-1 receptor type-1 on endothelial cells attenuated stress-induced neuroinflammation and prevented anxiety-like behavior. J. Neurosci. 34, 2583–2591 (2014).

103 Wohleb, E. S., Powell, N. D., Godbout, J. P. & Sheridan, J. F. Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. J. Neurosci. 33, 13820–13833 (2013).

104 Wohleb, E. S. et al. Peripheral innate immune challenge exaggerated microglia activation, increased the number of inflammatory CNS macrophages, and prolonged social withdrawal in socially defeated mice. Psychoneuroendocrinology 37, 1491–1505 (2012).

105 Wohleb, E. S. et al. β-adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J. Neurosci. 31, 6277–6288 (2011).

106 Hodes, G. E. et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc. Natl Acad. Sci. USA 111, 16136–16141 (2014).

107 McKim, D. B. et al. Sympathetic release of splenic monocytes promotes recurring anxiety following repeated social defeat. Biol. Psychiatry 79, 803–813 (2016).

108 Wohleb, E. S. et al. Re-establishment of anxiety in stress-sensitized mice is caused by monocyte trafficking from the spleen to the brain. Biol. Psychiatry 75, 970–981 (2014).

109 Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841–845 (2010). Using transgenic mice, this study provides direct evidence that microglia populate the brain early during neurodevelopment and do not undergo renewal from blood-derived myeloid cells.

110 Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8, 752–758 (2005).

111 Kettenmann, H., Hanisch, U. K., Noda, M. & Verkhratsky, A. Physiology of microglia. Physiol. Rev. 91, 461–553 (2011).

112 Ransohoff, R. M. & Perry, V. H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27, 119–145 (2009).

113 Kierdorf, K. & Prinz, M. Factors regulating microglia activation. Front. Cell. Neurosci. 7, 44 (2013).

114 Butovsky, O. et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131–143 (2014). This preclinical work reveals that gene expression and function in microglia are driven by brain-specific signals, such as TGFβ, that can contribute to deleterious microglial function.

115 Elmore, M. R. et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380–397 (2014). This study uncovers a requirement for CSF1 signalling in maintaining microglial function under physiological conditions, and shows that repopulation of microglia occurs via amplification of intrinsic progenitor cells.

116 Wang, Y. et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat. Immunol. 13, 753–760 (2012).

117 Biber, K., Neumann, H., Inoue, K. & Boddeke, H. W. Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci. 30, 596–602 (2007).

118 Jurgens, H. A. & Johnson, R. W. Dysregulated neuronal-microglial cross-talk during aging, stress and inflammation. Exp. Neurol. 233, 40–48 (2010).

119 Paolicelli, R. C. et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456–1458 (2011). Seminal findings showing that microglia contribute to synaptic refinement of hippocampal neurons during development and that reduced microglial function leads to persistence of immature synapses and altered neurodevelopment.

120 Zhan, Y. et al. Deficient neuron–microglia signaling results in impaired functional brain connectivity and social behavior. Nat. Neurosci. 17, 400–406 (2014).

121 Rogers, J. T. et al. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J. Neurosci. 31, 16241–16250 (2011).

122 Tremblay, M. E. et al. The role of microglia in the healthy brain. J. Neurosci. 31, 16064–16069 (2011).

123 Gyoneva, S. & Traynelis, S. F. Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J. Biol. Chem. 288, 15291–15302 (2013).

124 Fontainhas, A. M. et al. Microglial morphology and dynamic behavior is regulated by ionotropic glutamatergic and GABAergic neurotransmission. PLoS ONE 6, e15973 (2011).

125 Pocock, J. M. & Kettenmann, H. Neurotransmitter receptors on microglia. Trends Neurosci. 30, 527–535 (2007).

126 Tremblay, M. E., Lowery, R. L. & Majewska, A. K. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 8, e1000527 (2010).

127 Wake, H., Moorhouse, A. J., Jinno, S., Kohsaka, S. & Nabekura, J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci. 29, 3974–3980 (2009).

128 Schafer, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691–705 (2012).

129 Davies, L. C., Jenkins, S. J., Allen, J. E. & Taylor, P. R. Tissue-resident macrophages. Nat. Immunol. 14, 986–995 (2013).

130 Frank, M. G., Thompson, B. M., Watkins, L. R. & Maier, S. F. Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain Behav. Immun. 26, 337–345 (2012).

131 Frank, M. G., Miguel, Z. D., Watkins, L. R. & Maier, S. F. Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav. Immun. 24, 19–30 (2010).

132 Frank, M. G., Baratta, M. V., Sprunger, D. B., Watkins, L. R. & Maier, S. F. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav. Immun. 21, 47–59 (2007).

133 Chang, Y. et al. Inhibitory effects of ketamine on lipopolysaccharide-induced microglial activation. Mediators Inflamm. 2009, 705379 (2009).

134 Nair, A. & Bonneau, R. H. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J. Neuroimmunol. 171, 72–85 (2006).

135 Glezer, I. & Rivest, S. Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist 10, 538–552 (2004).

136 Sorrells, S. F. & Sapolsky, R. M. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav. Immun. 21, 259–272 (2007).

137 Weber, M. D., Frank, M. G., Sobesky, J. L., Watkins, L. R. & Maier, S. F. Blocking toll-like receptor 2 and 4 signaling during a stressor prevents stress-induced priming of neuroinflammatory responses to a subsequent immune challenge. Brain Behav. Immun. 32, 112–121 (2013).

138 Pereira, D. B. et al. Life stress, negative mood states, and antibodies to heat shock protein 70 in endometrial cancer. Brain Behav. Immun. 24, 210–214 (2010).

139 Sriram, K., Rodriguez-Fernandez, M. & Doyle, F. J. III . A detailed modular analysis of heat-shock protein dynamics under acute and chronic stress and its implication in anxiety disorders. PLoS ONE 7, e42958 (2012).

140 Zlatkovic, J., Bernardi, R. E. & Filipovic, D. Protective effect of Hsp70i against chronic social isolation stress in the rat hippocampus. J. Neural Transm. 121, 3–14 (2014).

141 Weber, M. D., Frank, M. G., Tracey, K. J., Watkins, L. R. & Maier, S. F. Stress induces the danger-associated molecular pattern HMGB-1 in the hippocampus of male Sprague Dawley rats: a priming stimulus of microglia and the NLRP3 inflammasome. J. Neurosci. 35, 316–324 (2015). Primary findings showing that stress-induced HMGB1 release in the hippocampus causes priming of microglia through increased NLRP3 activation, leading to amplified pro-inflammatory cytokine responses to stimulation by endotoxin.

142 Wu, T. Y. et al. High-mobility group box-1 was released actively and involved in LPS induced depressive-like behavior. J. Psychiatr. Res. 64, 99–106 (2015).

143 Emanuele, E. et al. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with different psychiatric disorders. Neurosci. Lett. 487, 99–102 (2011).

144 Aguirre, A., Maturana, C. J., Harcha, P. A. & Saez, J. C. Possible involvement of TLRs and hemichannels in stress-induced CNS dysfunction via mastocytes, and glia activation. Mediators Inflamm. 2013, 893521 (2013).

145 Verkhratsky, A., Krishtal, O. A. & Burnstock, G. Purinoceptors on neuroglia. Mol. Neurobiol. 39, 190–208 (2009).

146 Boucsein, C. et al. Purinergic receptors on microglial cells: functional expression in acute brain slices and modulation of microglial activation in vitro. Eur. J. Neurosci. 17, 2267–2276 (2003).

147 Ogata, T. et al. Adenosine triphosphate inhibits cytokine release from lipopolysaccharide-activated microglia via P2y receptors. Brain Res. 981, 174–183 (2003).

148 Seo, D. R. et al. Cross talk between P2 purinergic receptors modulates extracellular ATP-mediated interleukin-10 production in rat microglial cells. Exp. Mol. Med. 40, 19–26 (2008).

149 Harry, G. J. Microglia during development and aging. Pharmacol. Ther. 139, 313–326 (2013).

150 Basso, A. M. et al. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav. Brain Res. 198, 83–90 (2009).

151 Halmai, Z. et al. Associations between depression severity and purinergic receptor P2RX7 gene polymorphisms. J. Affect. Disord. 150, 104–109 (2013).

152 Lucae, S. et al. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum. Mol. Genet. 15, 2438–2445 (2006).

153 McQuillin, A. et al. Case–control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. Mol. Psychiatry 14, 614–620 (2009).

154 Stokes, L. et al. Two haplotypes of the P2X7 receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1β secretion. FASEB J. 24, 2916–2927 (2010).

155 Li, Y., Du, X. F., Liu, C. S., Wen, Z. L. & Du, J. L. Reciprocal regulation between resting microglial dynamics and neuronal activity in vivo. Dev. Cell 23, 1189–1202 (2012).

156 Perrotti, L. I. et al. Induction of ΔFosB in reward-related brain structures after chronic stress. J. Neurosci. 24, 10594–10602 (2004).

157 Walker, F. R., Nilsson, M. & Jones, K. Acute and chronic stress-induced disturbances of microglial plasticity, phenotype and function. Curr. Drug Targets 14, 1262–1276 (2013).

158 Yirmiya, R., Rimmerman, N. & Reshef, R. Depression as a microglial disease. Trends Neurosci. 38, 637–658 (2015).

159 Grabert, K. et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat. Neurosci. 19, 504–516 (2016).

160 Hinwood, M., Morandini, J., Day, T. A. & Walker, F. R. Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex. Cereb. Cortex 22, 1442–1454 (2012).

161 Wood, S. K. et al. Inflammatory factors mediate vulnerability to a social stress-induced depressive-like phenotype in passive coping rats. Biol. Psychiatry 78, 38–48 (2015).

162 Kreisel, T. et al. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol. Psychiatry 19, 699–709 (2014). This study provides compelling findings showing that short-term stress causes microglial activation and that chronic stress exposure promotes dystrophic microglial responses in the hippocampus, both contributing to the development of depressive-like behaviours.

163 Delpech, J. C. et al. Microglia in neuronal plasticity: influence of stress. Neuropharmacology 96, 19–28 (2015).

164 Boersma, M. C. et al. A requirement for nuclear factor-κB in developmental and plasticity-associated synaptogenesis. J. Neurosci. 31, 5414–5425 (2011).

165 Christoffel, D. J. et al. IκB kinase regulates social defeat stress-induced synaptic and behavioral plasticity. J. Neurosci. 31, 314–321 (2011).

166 Koo, J. W., Russo, S. J., Ferguson, D., Nestler, E. J. & Duman, R. S. Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc. Natl Acad. Sci. USA 107, 2669–2674 (2010).

167 Tanaka, K. et al. Prostaglandin E2-mediated attenuation of mesocortical dopaminergic pathway is critical for susceptibility to repeated social defeat stress in mice. J. Neurosci. 32, 4319–4329 (2012).

168 Goshen, I. et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol. Psychiatry 13, 717–728 (2008).

169 Goshen, I. & Yirmiya, R. Interleukin-1 (IL-1): a central regulator of stress responses. Front. Neuroendocrinol. 30, 30–45 (2009).

170 Koo, J. W. & Duman, R. S. IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl Acad. Sci. USA 105, 751–756 (2008).

171 McKim, D. B. et al. Neuroinflammatory dynamics underlie memory impairments after repeated social defeat. J. Neurosci. 36, 2590–2604 (2016).

172 Liu, M. et al. Microglia activation regulates GluR1 phosphorylation in chronic unpredictable stress-induced cognitive dysfunction. Stress 18, 96–106 (2015).

173 Warner-Schmidt, J. L., Vanover, K. E., Chen, E. Y., Marshall, J. J. & Greengard, P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl Acad. Sci. USA 108, 9262–9267 (2011).

174 Yirmiya, R. & Goshen, I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25, 181–213 (2011).

175 Yu, H. et al. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J. Neurosci. 32, 4092–4101 (2012).

176 Berton, O. et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311, 864–868 (2006).

177 Parkhurst, C. N. et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596–1609 (2013).

178 Banasr, M. et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol. Psychiatry 15, 501–511 (2010).

179 Guloksuz, S., Rutten, B. P., Arts, B., van Os, J. & Kenis, G. The immune system and electroconvulsive therapy for depression. J. ECT 30, 132–137 (2014).

180 Perez-Caballero, L. et al. Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs. Mol. Psychiatry 19, 607–614 (2014).

181 Beattie, E. C. et al. Control of synaptic strength by glial TNFα. Science 295, 2282–2285 (2002). A fundamental study elucidating the mechanisms by which glial-derived TNF modulates baseline levels of synaptic plasticity by trafficking of AMPA receptors.

182 Stellwagen, D. & Malenka, R. C. Synaptic scaling mediated by glial TNF-α. Nature 440, 1054–1059 (2006).

183 Stellwagen, D., Beattie, E. C., Seo, J. Y. & Malenka, R. C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-α. J. Neurosci. 25, 3219–3228 (2005).

184 Qiu, Z., Sweeney, D. D., Netzeband, J. G. & Gruol, D. L. Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons. J. Neurosci. 18, 10445–10456 (1998).

185 Gruol, D. L. & Nelson, T. E. Purkinje neuron physiology is altered by the inflammatory factor interleukin-6. Cerebellum 4, 198–205 (2005).

186 Qian, J. et al. Interleukin-1R3 mediates interleukin-1-induced potassium current increase through fast activation of Akt kinase. Proc. Natl Acad. Sci. USA 109, 12189–12194 (2012).

187 Milior, G. et al. Fractalkine receptor deficiency impairs microglial and neuronal responsiveness to chronic stress. Brain Behav. Immun. http://dx.doi.org/10.1016/j.bbi.2015.07.024 (2015). An initial report showing that hippocampal microglial processes have increased dendritic and synaptic elements following chronic stress, and that CX 3 CR1 mediates these synaptic as well as behavioural (anhedonia) deficits.

188 Walsh, J. G., Muruve, D. A. & Power, C. Inflammasomes in the CNS. Nat. Rev. Neurosci. 15, 84–97 (2014).

189 Guo, H., Callaway, J. B. & Ting, J. P. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677–687 (2015).

190 Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821–832 (2010).

191 Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228–232 (2006).

192 Alcocer-Gomez, E. et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav. Immun. 36, 111–117 (2014). Clinical work reporting that depressed individuals have elevated levels of NLRP3 inflammasome proteins in peripheral mononuclear immune cells, suggesting that this is a common molecular pathway leading to enhanced inflammation.

193 Zhang, Y. et al. NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation. Int. J. Neuropsychopharmacol. 18, pyv006 (2015).

194 Alcocer-Gomez, E. et al. Stress-induced depressive behaviors require a functional NLRP3 inflammasome. Mol. Neurobiol. http://dx.doi.org/10.1007/s12035-015-9408-7 (2015).

195 Iwata, M. et al. Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor. Biol. Psychiatry http://dx.doi.org/10.1016/j.biopsych.2015.11.026 (2015).

196 Krishnan, V. & Nestler, E. J. Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry 167, 1305–1320 (2010).

197 Walker, F. R. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology 67, 304–317 (2013).

198 Baune, B. T. & Eyre, H. Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report. J. Med. Case Rep. 4, 6 (2010).

199 O'Brien, S. M., Scott, L. V. & Dinan, T. G. Antidepressant therapy and C-reactive protein levels. Br. J. Psychiatry 188, 449–452 (2006).

200 Hannestad, J., DellaGioia, N. & Bloch, M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36, 2452–2459 (2011).

201 Hannestad, J., DellaGioia, N., Ortiz, N., Pittman, B. & Bhagwagar, Z. Citalopram reduces endotoxin-induced fatigue. Brain Behav. Immun. 25, 256–259 (2011).

202 Tynan, R. J. et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav. Immun. 26, 469–479 (2012).

203 Ramirez, K., Shea, D. T., McKim, D. B., Reader, B. F. & Sheridan, J. F. Imipramine attenuates neuroinflammatory signaling and reverses stress-induced social avoidance. Brain Behav. Immun. 46, 212–220 (2015).

204 Maes, M., Song, C. & Yirmiya, R. Targeting IL-1 in depression. Expert Opin. Ther. Targets 16, 1097–1112 (2012).

205 Raison, C. L. et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 31–41 (2013).

206 Krishnan, R. et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br. J. Dermatol. 157, 1275–1277 (2007).

207 Tyring, S. et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367, 29–35 (2006).

208 Akhondzadeh, S. et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 26, 607–611 (2009).

209 Muller, N. et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11, 680–684 (2006).

210 Na, K. S., Lee, K. J., Lee, J. S., Cho, Y. S. & Jung, H. Y. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 48, 79–85 (2014).

211 Eyre, H. A., Air, T., Proctor, S., Rositano, S. & Baune, B. T. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 57, 11–16 (2015).

212 Fleshner, M. Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome. Brain Behav. Immun. 27, 1–7 (2013).

213 Yamanashi, T. et al. NLRP3 inflammasome is activated by psychological stress: a potential role of NLRP3 inhibitor β-hydroxybutyrate's antidepressant effect. Program No. 775.05/G34. 2015 Neuroscience Meeting Planner (Society for Neuroscience, Washington, DC, 2015).

214 Ota, K. T. & Duman, R. S. Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression. Neurobiol. Dis. 57, 28–37 (2012).

215 Eyre, H. A., Papps, E. & Baune, B. T. Treating depression and depression-like behavior with physical activity: an immune perspective. Front. Psychiatry 4, 3 (2013).

216 Vukovic, J., Colditz, M. J., Blackmore, D. G., Ruitenberg, M. J. & Bartlett, P. F. Microglia modulate hippocampal neural precursor activity in response to exercise and aging. J. Neurosci. 32, 6435–6443 (2012).

217 Schloesser, R. J., Lehmann, M., Martinowich, K., Manji, H. K. & Herkenham, M. Environmental enrichment requires adult neurogenesis to facilitate the recovery from psychosocial stress. Mol. Psychiatry 15, 1152–1163 (2010).

218 Lehmann, M. L., Brachman, R. A., Martinowich, K., Schloesser, R. J. & Herkenham, M. Glucocorticoids orchestrate divergent effects on mood through adult neurogenesis. J. Neurosci. 33, 2961–2972 (2013).

219 Goshen, I. et al. Environmental enrichment restores memory functioning in mice with impaired IL-1 signaling via reinstatement of long-term potentiation and spine size enlargement. J. Neurosci. 29, 3395–3403 (2009).

220 DeVries, A. C., Craft, T. K., Glasper, E. R., Neigh, G. N. & Alexander, J. K. 2006 Curt P. Richter award winner: social influences on stress responses and health. Psychoneuroendocrinology 32, 587–603 (2007).

221 Bailey, M. T. Influence of stressor-induced nervous system activation on the intestinal microbiota and the importance for immunomodulation. Adv. Exp. Med. Biol. 817, 255–276 (2014).

222 Galley, J. D. & Bailey, M. T. Impact of stressor exposure on the interplay between commensal microbiota and host inflammation. Gut Microbes 5, 390–396 (2014).

223 Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16, 22–34 (2015).